SENS - Senseonics stock rises ~5% after hours on Q2 results beat unchanged FY revenue guidance
- Shares of Senseonics ( NYSE: SENS ) gained 5.4% to $1.96 in Tuesday postmarket trading, after the company reported Q2 results that beat estimates and kept it FY 2022 revenue guidance unchanged.
- Germantown, Md.-based SENS is medical device company catering to diabetics. Its flagship product is the Eversense E3 continuous glucose monitoring system.
- SENS posted Q2 GAAP EPS of $0.22 which beat estimates by $0.26 . Its Q2 revenue of $3.7M rose 12.1% Y/Y and beat by $0.12M .
- The company also reaffirmed its FY 2022 global net revenue guidance of $14M to $18M. The consensus revenue estimate is $16.83M.
- Last week, SENS said it had received a positive coverage decision for the Eversense E3 system from Anthem, now called Elevance Health ( ELV ), added over 45M covered lives for the system.
- Investors reacted favorably to the news and saw the decision as a revenue booster. SENS stock closed more than 20% higher on both Aug. 3 and 4 .
For further details see:
Senseonics stock rises ~5% after hours on Q2 results beat, unchanged FY revenue guidance